Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD reports publication of Zolinza data

MSD reports publication of Zolinza data

23rd July 2007

Merck, Sharp and Dohme (MSD) has announced the publication of clinical trial data for its treatment for advanced, refractory cutaneous T-cell lymphoma (CTCL), Zolinza (vorinostat), with the data presented in the Journal of Clinical Oncology.

The study showed that 30 per cent of CTCL patients achieved an objective response to the compound – the primary endpoint of the study – while the objective response rate for patients with stage IIb of the disease or higher was also 30 per cent.

Zolinza is the company’s most recent anticancer medication, the histone deacetylase inhibitor being approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in CTCL patients with progressive or recurrent forms of the disease following the administration of two systemic therapies.

Elise Olsen, director of the Cutaneous Lymphoma Treatment and Research Centre at Duke University Medical Centre, said: “The findings from this clinical study are quite encouraging, particularly given that the effect of Zolinza was evaluated based on stringent criteria to determine objective response.”

She added that the effect of the compound was also consistent in patients in later stages of the disease and the entire patient group tested.

In June 2006, MSD announced the results of a pivotal phase II clinical trial of Zolinza, with positive trial results suggesting the compound could be at the forefront of a “new and promising class” of anticancer drugs.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.